Scott S. Tykodi, MD of Seattle Cancer Care Alliance discusses the recently released Checkmate 214 data and how favorable RCC patients may be better served staying on targeted therapies rather than immunotherapy treatments.
Checkmate 214 Data Favorable RCC Patients Better on Targeted Therapies
